The dilutive offering will increase share count by ~22% (excluding warrants), likely pressuring RGNX shares near-term as the market absorbs supply. Monitor for use of proceeds toward pipeline programs (RGX-202, ABBV-RGX-314, NAVSUNLI) and any clinical updates that could offset dilution sentiment.
Drugs in focus
RGNX drug pipeline →surabgene lomparvovec
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If positive Phase 3 data in Q4 2026, regulatory filing likely 2027 with potential FDA approval 2028 for wet AMD (subretinal). Diabetic retinopathy program (NAAVIGATE) is Phase IIb/III and further out.
- Next catalyst
- None dated
What to watchWatch for topline Phase 3 data from ATMOSPHERE/ASCENT in Q4 2026, this is the single biggest binary event for RGNX. Interim ALTITUDE data at ASRS July 2026 provides a near-term sentiment check. The $100M AbbVie milestone extends cash runway into late 2027, reducing near-term dilution risk.
- ◆ NAVSUNLI 6/10 BLA resubmission pending (accelerated approval) — prior BLA reached PDUFA Feb 8, 2026 and received a Complete Response L Named in filing
- ◆ RGX-202 6/10 Phase 3 (pivotal topline complete; BLA submission planned) Named in filing
- ▼ RGX-111 2/10 Phase I/II (on FDA clinical hold since January 2026) Named in filing
- All RGNX drugs, catalysts & trials →
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 20 $10.32entry
- T+1 · 4mo ago +0.19%α −0.64% · $10.34
- T+5 · 4mo ago −5.72%α −5.29% · $9.73
- T+20 · 3mo ago +9.79%α +5.67% · $11.33
- T+60 · 5w ago −29.65%α −34.49% · $7.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
REGENXBIO priced a public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant. Underwriters fully exercised their option for an additional 1,667,250 shares. Net proceeds are expected to be approximately $107.8 million. The offering closes July 20, 2026.
Key Facts
- Priced 10,003,889 shares at $9.00/share and 1,111,111 pre-funded warrants at $8.9999/warrant
- Underwriters exercised option in full for 1,667,250 additional shares
- Net proceeds expected to be approximately $107.8 million
- Pre-funded warrants have $0.0001 exercise price, exercisable at any time with no expiration
- Offering expected to close July 20, 2026
Financial Impact
Dilution of approximately 22% from new shares alone, plus potential dilution from 1,111,111 warrant shares; net proceeds of ~$107.8M added to cash position
Risk Factors
- Significant dilution to existing shareholders
- Potential overhang from pre-funded warrants exercisable at $0.0001
- Clinical-stage biotech with no approved products; capital needs may require further offerings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-308342 |
| Document: d40931dex41.htm | 0001193125-26-308342 |
| Document: d40931d8k.htm | 0001193125-26-308342 |
| Document: d40931dex51.htm | 0001193125-26-308342 |
| Document: d40931dex991.htm | 0001193125-26-308342 |
| Document: 0001193125-26-308342-index-headers.html | 0001193125-26-308342 |
| Document: 0001193125-26-308342-index.html | 0001193125-26-308342 |
| Document: 0001193125-26-308342.txt | 0001193125-26-308342 |
Track record
15 reports on RGNX
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.36% at T+5 after the Jun 29, 2026 report. 2 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
- Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
- Aug 25, 202611w ago 8-K Neutral 3/10 Entry $9.38 Now $7.32 −21.96% settles Nov 19
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
- Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
- Jul 20, 202617w ago 8-K Bearish 6/10 Viewing Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers